{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:22:47Z","timestamp":1791728567645,"version":"4.3.4"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"Importance<\/jats:title>Transthyretin cardiac amyloidosis (ATTR-CA) is an underdiagnosed but treatable cause of heart failure (HF) in older individuals that occurs in the context of normal wild-type (ATTRwt-CA) or an abnormal inherited (ATTRv-CA) TTR<\/jats:italic> gene variant. While the most common inherited TTR<\/jats:italic> variant, V142I, occurs in 3% to 4% of self-identified Black Americans and is associated with excess morbidity and mortality, the prevalence of ATTR-CA in this at-risk population is unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To define the prevalence of ATTR-CA and proportions attributable to ATTRwt-CA or ATTRv-CA among older Black and Caribbean Hispanic individuals with HF.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective, multicenter, cross-sectional study was conducted in several major US cities (Boston, Massachusetts; New York, New York; and New Haven, Connecticut) among individuals who self-identified as Black or Caribbean Hispanic older than 60 years with HF. Participants were enrolled between May 2019 and June 2024, and data analysis was conducted from June 2024 to May 2025.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>ATTR-CA was determined by radionuclide imaging, with blood testing to exclude light-chain amyloidosis and genotyping to determine TTR<\/jats:italic> gene variant. Echocardiographic, biochemical, physical performance, and quality-of-life data were collected.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 646 participants, median (IQR) participant age was 73 (66-80) years, 329 (50.6%) were women, 550 (85.1%) identified as Black, and 186 (28.8%) identified as Caribbean Hispanic. Median (IQR) left ventricular wall thickness was 13 (12-14) mm, and median (IQR) left ventricular ejection fraction was 61% (55%-66%). Overall prevalence of ATTR-CA was 6.66% (95% CI, 4.73%-8.58%), of whom 24 (55.8%) had ATTRwt-CA and 19 (44.2%) had ATTRv-CA owing to V142I. Overall prevalence of V142I allele was 5.6%, and of those, 19 (52.8%) had ATTRv-CA. Prevalence of ATTR-CA was 8.15% (95% CI, 5.15%-11.15%) in men and 5.20% (95% CI, 2.79%-7.61%) in women (P<\/jats:italic>\u2009=\u2009.13). Prevalence of ATTR-CA was 7.82% (95% CI, 5.57%-10.06%) in Black participants and 2.15% (95% CI, 0.07%-4.24%) in Hispanic participants (P<\/jats:italic>\u2009=\u2009.004). Among Black participants aged 75 years or younger, ATTR-CA was observed in 3.42% of participants (95% CI, 1.43%-5.40%) compared to 14.04% (95% CI, 9.53%-18.54%) of those older than 75 years (P<\/jats:italic>\u2009&amp;lt;\u2009.001). Among Black male participants older than 75 years, prevalence of ATTR-CA was 17.17% (95% CI, 9.74%-24.60%).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study, ATTR-CA was an important cause of HF in older Black individuals with HF, particularly in men older than 75 years. Approximately half of V142I carriers with HF had ATTR-CA, while 55.8% of all ATTR-CA cases had normal TTR<\/jats:italic> genotype.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03812172<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2025.2948","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:00:23Z","timestamp":1757516423000},"page":"1034","source":"Crossref","is-referenced-by-count":27,"title":["Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure"],"prefix":"10.1001","volume":"10","author":[{"given":"Frederick L.","family":"Ruberg","sequence":"first","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"},{"name":"Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Teruya","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Helmke","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dia A.","family":"Smiley","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Fine","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Kurian","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Harlem Hospital Center, New York City Health and Hospital Corporation, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farbod","family":"Raiszadeh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Harlem Hospital Center, New York City Health and Hospital Corporation, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Prokaeva","sequence":"additional","affiliation":[{"name":"Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Spencer","sequence":"additional","affiliation":[{"name":"Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Wong","sequence":"additional","affiliation":[{"name":"Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivda","family":"Pandey","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Blaner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"DeLuca","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona P.","family":"Kinkhabwala","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Leb","sequence":"additional","affiliation":[{"name":"Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiva","family":"Mintz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"LaValley","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Einstein","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"},{"name":"Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cohn","sequence":"additional","affiliation":[{"name":"Feinstein Institutes of Medical Research, Northwell Health, Manhasset, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesia","family":"Gallegos","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Murtagh","sequence":"additional","affiliation":[{"name":"Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery W.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Departments of Chemistry and Molecular Medicine, Scripps Research Institute, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Miller","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"hoi250045r1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review.","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"issue":"22","key":"hoi250045r2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hoi250045r3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"issue":"7","key":"hoi250045r4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans.","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"issue":"21","key":"hoi250045r5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2024.4467","article-title":"Cardiovascular burden of the V142I transthyretin variant.","volume":"331","author":"Selvaraj","year":"2024","journal-title":"JAMA"},{"issue":"22","key":"hoi250045r6","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry.","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"issue":"14","key":"hoi250045r7","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jama.2022.2896","article-title":"Association of transthyretin Val122Ile variant with incident heart failure among Black individuals.","volume":"327","author":"Parcha","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"hoi250045r8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly Black Americans.","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"issue":"38","key":"hoi250045r9","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi250045r10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"38","key":"hoi250045r11","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"hoi250045r12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis.","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hoi250045r13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.122.014938","article-title":"Identification of transthyretin cardiac amyloidosis among patients previously diagnosed with hypertrophic cardiomyopathy.","volume":"15","author":"Rowin","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"hoi250045r14","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/ehf2.14971","article-title":"Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.","volume":"11","author":"Garcia-Pavia","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"2","key":"hoi250045r15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi250045r16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi250045r17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"hoi250045r18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028534","article-title":"Design and rationale the SCAN-MP (screening for cardiac amyloidosis with nuclear imaging in minority populations) study.","volume":"12","author":"Ruberg","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"hoi250045r19","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/eurjpc\/zwae093","article-title":"Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.","volume":"31","author":"Aimo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"hoi250045r20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/13506129.2024.2398446","article-title":"International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction.","volume":"31","author":"Yun","year":"2024","journal-title":"Amyloid"},{"issue":"4","key":"hoi250045r21","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1002\/ehf2.13360","article-title":"Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.","volume":"8","author":"Devesa","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"12","key":"hoi250045r22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jcmg.2023.05.002","article-title":"Development and validation of a prediction model and score for transthyretin cardiac amyloidosis diagnosis: T-Amylo.","volume":"16","author":"Arana-Achaga","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10","key":"hoi250045r23","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"6","key":"hoi250045r24","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.cardfail.2023.11.017","article-title":"EstimATTR: a simplified, machine-learning-based tool to predict the risk of wild-type transthyretin amyloid cardiomyopathy.","volume":"30","author":"Casta\u00f1o","year":"2024","journal-title":"J Card Fail"},{"issue":"11","key":"hoi250045r25","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis.","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"hoi250045r26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamacardio.2021.6059","article-title":"High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning.","volume":"7","author":"Duffy","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"3","key":"hoi250045r27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study.","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"hoi250045r28","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"hoi250045r29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijcard.2022.12.048","article-title":"Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women.","volume":"374","author":"Prasad","year":"2023","journal-title":"Int J Cardiol"},{"issue":"21","key":"hoi250045r30","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1001\/jama.2024.2868","article-title":"Addressing health disparities-the case for variant transthyretin cardiac amyloidosis grows stronger.","volume":"331","author":"Maurer","year":"2024","journal-title":"JAMA"},{"key":"hoi250045r31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.amjcard.2024.01.009","article-title":"Race, genotype, and prognosis in Black patients with transthyretin cardiac amyloidosis.","volume":"216","author":"Khedraki","year":"2024","journal-title":"Am J Cardiol"},{"issue":"4","key":"hoi250045r32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hoi250045r33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jaccao.2021.07.002","article-title":"Genomic screening for pathogenic transthyretin variants finds evidence of underdiagnosed amyloid cardiomyopathy from health records.","volume":"3","author":"Carry","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"2","key":"hoi250045r34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ejhf.3088","article-title":"Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: distinct from wild-type transthyretin amyloidosis?","volume":"26","author":"Razvi","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"hoi250045r35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jcmg.2025.01.018","article-title":"Early detection of transthyretin cardiac amyloidosis using 124I-evuzamitide positron emission tomography\/computed tomography.","volume":"18","author":"Smiley","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"hoi250045r36","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.jchf.2024.06.014","article-title":"Differential association of transthyretin stability with variant and wild-type transthyretin amyloid cardiomyopathy: the SCAN-MP study.","volume":"12","author":"Urina-Jassir","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"12","key":"hoi250045r37","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange.","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry"},{"issue":"4","key":"hoi250045r38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.004668","article-title":"Health status variation across practices in outpatients with heart failure: insights from the CHAMP-HF (change the management of patients with heart failure) registry.","volume":"11","author":"Khariton","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2838853\/jamacardiology_ruberg_2025_oi_250045_1758588889.84171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:04:36Z","timestamp":1759935876000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2838853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.2948","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}